Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

Background The SUSTAIN 6 trial demonstrated that once-weekly semaglutide (0.5 and 1.0 mg) significantly reduced major adverse cardiovascular (CV) events (MACE) vs placebo in subjects with type 2 diabetes (T2D) and high CV risk. The effects of gender, age and baseline CV risk on outcomes are importan...

Full description

Saved in:

Bibliographic Details
Published in:	Cardiovascular diabetology Vol. 18; no. 1; pp. 73 - 12
Main Authors:	Leiter, Lawrence A., Bain, Stephen C., Hramiak, Irene, Jódar, Esteban, Madsbad, Sten, Gondolf, Theis, Hansen, Thomas, Holst, Ingrid, Lingvay, Ildiko
Format:	Journal Article
Language:	English
Published:	London BioMed Central 06.06.2019 Springer Nature B.V BMC
Subjects:	Age Age Factors Aged Angina pectoris Angiology Antidiabetics Baseline cardiovascular risk Blood pressure Body weight Cardiology Cardiovascular disease Cardiovascular diseases Cardiovascular Diseases - diagnosis Cardiovascular Diseases - mortality Cardiovascular Diseases - prevention & control Cardiovascular events Cerebral infarction Cholesterol Clinical medicine Clinical Trials, Phase III as Topic Coronary artery Coronary artery disease Demography Diabetes Diabetes mellitus Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - mortality Drug Administration Schedule Epidermal growth factor receptors Female Gender Gender differences Glucagon Glucagon-like peptide 1 Glucagon-Like Peptides - administration & dosage Glucagon-Like Peptides - adverse effects Health risk assessment Heart attacks Heart diseases Heart failure Heart surgery Hospitalization Humans Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - adverse effects Incretins - administration & dosage Incretins - adverse effects Ischemia Kidney diseases Male Medicine Medicine & Public Health Middle Aged Myocardial infarction Original Investigation Patients Protective Factors Randomized Controlled Trials as Topic Risk Assessment Risk Factors Semaglutide Sex Factors Smoking Stenosis Stroke Systematic review Time Factors Treatment Outcome Type 2 diabetes Type 2 diabetes Cardiovascular events Semaglutide Baseline cardiovascular risk Gender Cardiovascular outcome trial Age SUSTAIN 6
ISSN:	1475-2840, 1475-2840
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!